GC113 Can We Get Married Pre-marital, Pre-pregnancy And Pre-natal Counselling
Pre-marital, pre-pregnancy, and pre-natal counseling is a comprehensive genetic and medical assessment provided to couples before marriage, conception, or during pregnancy to identify hereditary disorders, optimize maternal-fetal health, and guide informed reproductive decision-making.
Pre-Marital, Pre-Pregnancy and Prenatal Counselling
Lecture Map
This lecture answers one deceptively simple question a couple may bring to any doctor: "Can we get married and should we have children?" The answer requires a systematic framework to identify reproductive risks (both maternal and fetal), mitigate them before or during pregnancy, and guide couples through the complex landscape of screening, diagnosis, and decision-making. The lecture spans the continuum from pre-marital health checks through pre-pregnancy optimization to antenatal screening and prenatal diagnosis.
- Understand reproductive risks — maternal and fetal
- Know how to identify risks (history, examination, screening tests)
- Understand options for at-risk couples
- Appreciate counselling concerns (ethics, communication, support)
This is a high-frequency exam topic because it intersects O&G, genetics, haematology, family medicine, and ethics. Past papers repeatedly test: thalassaemia carrier screening and counselling, antenatal screening schedule, invasive vs non-invasive prenatal testing, teratogenic medications, folic acid supplementation, and ethical principles around prenatal diagnosis and termination. You will encounter these in MCQs, SAQs, minicases, and OSCEs.
Why Pre-Pregnancy Counselling Matters — First Principles
The objective of pre-marital and pre-pregnancy counselling is to detect and assess any specific health problems in the woman or her partner that may be relevant and managed prior to pregnancy, AND to obtain general advice about optimizing personal health care and lifestyle. [1]
Why this matters from first principles: Many congenital anomalies occur in the first 4–8 weeks after conception — often before a woman even knows she is pregnant. Neural tube closure happens by day 28. Organogenesis is largely complete by week 12. If you wait until the booking visit to address teratogens, folate deficiency, or uncontrolled medical conditions, the window of prevention has already closed. This is why counselling should occur before conception.
Pre-pregnancy counselling is appropriate whether the reproductive-aged patient is currently using contraception or planning pregnancy. As health status and risk factors can change over time, pre-pregnancy counselling should occur several times during a woman's reproductive lifespan. [1]
Why repeated counselling? A 25-year-old with no medical history may develop diabetes, hypertension, or an autoimmune condition by age 32. Her medication list changes. New family history may emerge (e.g., a sibling's child born with a genetic condition). Each pregnancy also carries new risks (e.g., prior preeclampsia, gestational diabetes).
Reproductive Risks
Maternal reproductive risks include: pre-existing medical conditions, pregnancy-related complications, operative risk, and psychosocial problems. [1]
| Category | Examples | Why It Matters |
|---|---|---|
| Pre-existing medical conditions | DM, HTN, epilepsy, SLE, thyroid disease, cardiac disease, renal disease | Uncontrolled disease → worse maternal & fetal outcomes; some medications are teratogenic |
| Pregnancy-related complications | Preeclampsia, GDM, placenta praevia, APH, PPH | Prior Hx increases recurrence risk |
| Operative risk | Previous C-section, uterine surgery | Scar dehiscence/rupture risk in subsequent pregnancies |
| Psychosocial problems | Depression, IPV, substance use, lack of social support | Affects antenatal care compliance, maternal-fetal bonding, postnatal outcomes |
Fetal reproductive risks include: growth problems, congenital anomalies, infection, and birth trauma. [1]
Congenital anomalies can be: chromosomal/genetic, structural, or functional. [1]
| Category | Examples | Detection Method |
|---|---|---|
| Growth problems | IUGR, macrosomia | Serial USG, SFH measurement |
| Congenital anomalies — Chromosomal | Trisomy 21 (Down syndrome), Trisomy 18, Trisomy 13, Turner syndrome | Screening tests → invasive diagnosis |
| Congenital anomalies — Genetic | Thalassaemia, cystic fibrosis, SMA | Carrier screening → prenatal DNA analysis |
| Congenital anomalies — Structural | NTD, congenital heart defects, renal anomalies | Morphology scan 18–22 weeks |
| Congenital anomalies — Functional | Congenital hypothyroidism | Neonatal screening (not prenatal) |
| Infection | Rubella, CMV, toxoplasmosis, syphilis, HBV, HIV | Maternal serology, TORCH screen |
| Birth trauma | Shoulder dystocia, brachial plexus injury | Risk assessment → delivery planning |
Risk Identification: The Clinical Approach
1. History Taking [1]
This is the backbone of pre-pregnancy counselling. The lecture systematically covers:
Age is a key risk factor. [1]
- Why: Advanced maternal age ( ≥ 35 at delivery) increases risk of chromosomal aneuploidies (especially Trisomy 21), miscarriage, GDM, preeclampsia, placenta praevia, C-section. Paternal age > 40 also increases risk of new autosomal dominant mutations.
- Why: Certain genetic conditions cluster in specific ethnic groups. For HK Chinese, the most important is thalassaemia (α-thal and β-thal). In HK Chinese with low MCV: ~5% are α-thal carriers, ~3% are β-thal carriers, ~0.3% have HbE. Overall ~11.3% carry a thalassaemia allele. [3]
- Why: Consanguineous couples share a higher proportion of genes identical by descent → dramatically increased risk of autosomal recessive conditions. First cousins share ~12.5% of their genome; their offspring has ~6.25% chance of being homozygous at any given locus.
If high risk of a chromosomal or genetic disorder based on family history, referral to pre-pregnancy genetic counselling is preferred to allow more reproductive options. [1]
Why pre-pregnancy referral is preferred: Before conception, the couple has the widest range of options: natural conception with prenatal diagnosis, preimplantation genetic testing (PGT) with IVF, use of donor gametes, adoption, or choosing not to have biological children. Once pregnant, options narrow to prenatal screening/diagnosis and decisions about continuation vs. termination.
The lecture shows pedigree diagrams for:
| Inheritance Pattern | Key Features | Examples |
|---|---|---|
| Autosomal dominant | 50% risk to each offspring; affected in every generation; male = female | Huntington's, Marfan syndrome, achondroplasia |
| Autosomal recessive | 25% risk if both parents carriers; may skip generations; consanguinity ↑ risk | Thalassaemia, CF, SMA, PKU |
| X-linked | Males predominantly affected; carrier females usually unaffected; no male-to-male transmission | Haemophilia, Duchenne MD, G6PD deficiency |
Discussion on how the medical condition may affect, or be affected by, a pregnancy. Stabilisation of pre-existing medical condition. Multidisciplinary pre-pregnancy planning. [1]
Key examples for exam:
| Condition | Effect on Pregnancy | Effect of Pregnancy on Condition | Pre-pregnancy Action |
|---|---|---|---|
| Epilepsy | AEDs → teratogenicity (NTD, cleft palate, CHD) | Seizure frequency may change | Switch to lamotrigine/levetiracetam monotherapy at lowest effective dose; folic acid 5 mg/day (high dose because AEDs deplete folate) [5] |
| Diabetes | ↑ congenital anomalies (NTD, cardiac), macrosomia, stillbirth | Insulin requirements change each trimester | Optimize HbA1c < 6.5% pre-conception; switch from oral hypoglycaemics to insulin if needed |
| Hypertension | Superimposed preeclampsia, IUGR, placental abruption | BP may initially fall then rise | Stop ACEi/ARB (teratogenic); switch to labetalol/nifedipine/methyldopa |
| SLE | Flare, preeclampsia, IUGR, neonatal lupus (anti-Ro → congenital heart block) | Flares common, especially postpartum | Quiescent disease for ≥ 6 months; continue hydroxychloroquine; stop cyclophosphamide/methotrexate/mycophenolate |
| Thyroid disease | Graves' → neonatal thyrotoxicosis; Hypothyroid → developmental delay | hCG stimulates thyroid | Switch MMZ/CMZ to PTU in 1st trimester (CMZ/MMZ associated with aplasia cutis and choanal atresia); switch back to MMZ in 2nd trimester due to PTU hepatotoxicity [2] |
Review current medications including over the counter on appropriateness and teratogenic potential. May need adjustment of medication prior to pregnancy to optimize disease control and minimize teratogenic risk. [1]
High-Yield Teratogens to Know
Common teratogenic drugs that MUST be stopped or switched pre-pregnancy:
- ACEi/ARBs → renal dysgenesis, oligohydramnios, skull hypoplasia
- Warfarin → nasal hypoplasia, stippled epiphyses, CNS anomalies (especially 6–9 weeks); switch to LMWH [4]
- Methotrexate → aminopterin syndrome; stop ≥ 3 months before conception
- Valproate → NTD (1–2%), facial dysmorphism, developmental delay
- Isotretinoin (Accutane) → craniofacial, cardiac, CNS defects; stop ≥ 1 month before conception
- Statins → theoretical teratogenicity (cholesterol needed for embryogenesis)
- Mycophenolate → ear, facial, limb anomalies
- Lithium → Ebstein anomaly (though risk lower than historically thought)
- Previous uterine surgery → scar integrity concerns
- Drug allergies → important for labour/anaesthesia planning
- Occupation → exposure to radiation, chemicals, infections (healthcare workers, lab staff, teachers)
Smoking, alcohol and substance use should be stopped before conception. No known safe level of alcohol consumption during pregnancy. Considered for both parents when relevant. [1]
- Smoking: ↑ risk of IUGR, preterm labour, placental abruption, SIDS. Nicotine and CO cross the placenta.
- Alcohol: Fetal alcohol spectrum disorder (FASD) — growth restriction, facial features, neurodevelopmental impairment. No safe threshold.
- Substance use: Cocaine → placental abruption, IUGR; Opioids → neonatal abstinence syndrome.
- STI risk, intimate partner violence (IPV): Screen sensitively. IPV often escalates during pregnancy.
Well balanced diet. Weight management. Periconceptional folic acid supplementation. [1]
Folic Acid Supplementation — Key Details
Standard dose: 0.4–0.5 mg daily, starting ≥ 1 month (ideally 3 months) before conception through the first 12 weeks of pregnancy.
High dose (5 mg daily): For women on AEDs, those with prior NTD-affected pregnancy, diabetics, BMI > 30, on methotrexate. [5]
Why: Folate is essential for DNA synthesis and neural tube closure (completes by day 28 post-conception). Deficiency → neural tube defects (spina bifida, anencephaly).
- Weight management: BMI < 18.5 → anovulation, IUGR; BMI ≥ 30 → GDM, preeclampsia, macrosomia, NTD, increased anaesthetic risk.
Hepatitis B, rubella and varicella immunization can be considered for women with incomplete immunity. Seasonal influenza vaccination in pregnancy is safe. [1]
| Vaccine | Timing | Why |
|---|---|---|
| Rubella (MMR) | Pre-conception (live vaccine → wait ≥ 4 weeks before conceiving) | Congenital rubella syndrome: cataracts, deafness, CHD, IUGR |
| Varicella | Pre-conception (live vaccine) | Congenital varicella syndrome (limb hypoplasia, skin scarring, eye defects) |
| Hepatitis B | Pre-conception or antenatal | Prevent vertical transmission |
| Influenza (inactivated) | Safe in any trimester | Pregnant women at higher risk of severe influenza |
| COVID-19 | Safe in pregnancy (mRNA or inactivated) | Current recommendation |
Key rule: Live vaccines (MMR, varicella, BCG) are contraindicated during pregnancy. Inactivated vaccines (influenza, Tdap, HBV) are safe.
Travel and environmental risks — reduce the chance of infection. [1]
- Zika virus (teratogenic → microcephaly), malaria (severe in pregnancy), traveller's diarrhoea
- Advise postponing travel to endemic areas; chemoprophylaxis for malaria if travel unavoidable
Obstetric history: congenital anomalies, stillbirth, neonatal death, recurrent pregnancy loss, grand multiparity, difficult delivery, birth trauma. [1]
- Prior congenital anomaly → recurrence risk depends on aetiology (chromosomal vs. multifactorial vs. single gene)
- Stillbirth/neonatal death → investigate cause; may indicate genetic condition, placental insufficiency
- Recurrent pregnancy loss ( ≥ 3 consecutive losses < 24 weeks) → investigate: antiphospholipid syndrome, uterine anomaly, cervical incompetence, balanced translocation
- Grand multiparity ( ≥ 5 deliveries) → higher risk of malpresentation, PPH, placental problems
General examination: auscultation of heart sounds, breast examination, cervical screening, +/- other tests as indicated. Blood pressure, body mass index. [1]
| Component | What You're Looking For |
|---|---|
| BP | Baseline for comparison; chronic HTN if elevated |
| BMI | Underweight or obese → specific risks |
| Heart auscultation | Undiagnosed structural heart disease (especially mitral stenosis — poorly tolerated in pregnancy due to volume overload) |
| Breast examination | Exclude breast pathology before pregnancy/lactation |
| Cervical screening | Up-to-date Pap smear; cannot do colposcopy easily during pregnancy |
3. Screening Tests [1]
Complete blood picture (including Hb, MCV), blood group + Rhesus factor, infection screen (VDRL, Hepatitis B, rubella antibody, HIV antibody), cervical smear, urine protein and sugar. [1]
| Test | Purpose | Key Thresholds |
|---|---|---|
| CBP (Hb, MCV) | Detect anaemia; low MCV triggers thalassaemia workup | MCV < 82 fL → consider thalassaemia carrier |
| Blood group + Rh | Rh-negative mother at risk of alloimmunization | Anti-D prophylaxis if Rh-negative |
| VDRL | Syphilis screening | If positive → confirmatory FTA-ABS |
| HBsAg | Hepatitis B carrier status | Carrier → vertical transmission risk; neonatal HBIg + vaccination |
| Rubella antibody | Immunity status | Non-immune → vaccinate pre-conception |
| HIV antibody | HIV status (opt-out screening in HK) | If positive → cART to prevent MTCT |
| Cervical smear | Cervical cytology / HPV screening | Per HK guidelines |
| Urine protein/sugar | Baseline renal function, occult DM | Proteinuria → renal disease workup |
Available screening tests for low-risk women for carrier of more common genetic conditions (e.g., thalassaemia). [1]
This is a very high-yield topic for HKUMed exams. The 2023 Fourth Summative MCQ directly tested this. [9]
The HK Screening Strategy:
- Check MCV at booking visit
- If MCV ≤ 82 fL → check partner's MCV
- If both have low MCV → Hb electrophoresis (Hb pattern) for both
- Determine carrier status:
| Feature | α-Thalassaemia Carrier | β-Thalassaemia Carrier |
|---|---|---|
| MCV | < 82 fL | < 82 fL |
| HbA (α₂β₂) | Present | Present |
| HbA₂ (α₂δ₂) | Normal | Raised ( > 3.5%) |
| HbF (α₂γ₂) | Normal | May be raised |
| HbH inclusion bodies (β₄) | Positive | Negative |
| Iron studies | Normal or raised | Normal or raised |
Diagnosis of α-thalassaemia carrier: HbA₂ normal, HbF normal, HbH granules positive, MCV < 82 fL, Fe normal or raised. [1]
Diagnosis of β-thalassaemia carrier: HbA₂ raised, HbF raised, MCV < 82 fL, Fe normal or raised. [1]
Exam Trap: α-thal vs β-thal Carrier
The key discriminator is HbA₂ level: normal in α-thal carrier, RAISED in β-thal carrier. HbH inclusion bodies are specific for α-thal. Iron is normal or raised in both (distinguishes from iron deficiency anaemia where MCV is also low but iron/ferritin are LOW).
Why iron is important: Low MCV can be from iron deficiency OR thalassaemia. If iron is low, treat iron deficiency first, then recheck MCV. If MCV remains low despite iron repletion → thalassaemia screening.
Understanding the genetics (from the lecture diagrams):
- α-globin genes: 4 copies (2 on each chromosome 16). Deletions range from 1 (silent carrier, normal MCV) to 4 (Hb Bart's hydrops fetalis — incompatible with life).
- β-globin genes: 2 copies (1 on each chromosome 11). β⁺ (reduced production) or β⁰ (no production).
| # α-gene deletions | Clinical Phenotype | MCV |
|---|---|---|
| 1 deleted (αα/α-) | Silent carrier | Normal |
| 2 deleted (αα/-- or α-/α-) | α-thal trait | Low |
| 3 deleted (α-/--) | HbH disease | Very low; moderate anaemia |
| 4 deleted (--/--) | Hb Bart's hydrops fetalis | Incompatible with life; severe maternal complications |
Homozygous α-thalassaemia (4 deletions) is usually NOT compatible with life. Mother carrying an affected fetus has 50–60% chance of developing serious obstetric complications (preeclampsia and PPH). [6]
Expanded carrier screening is currently not funded by the public health system. Cost effectiveness, acceptance and uptake uncertain. Detailed pretest counselling on benefits and limitations of testing required. [1]
This is a panel-based approach testing for hundreds of recessive conditions simultaneously. Important counselling points: may reveal carrier status for conditions with uncertain clinical significance; psychological impact; not 100% detection rate.
Antenatal Screening Tests in Hong Kong [1]
This is the schedule used in HK public hospitals and is directly testable. [1]
| Gestation | Test | Purpose |
|---|---|---|
| First booking | Hb, MCV, HBsAg, Rubella Ab, VDRL/FTA-ABS, Rh blood group, Red cell antibodies, HIV (opt-out) | Baseline health; carrier detection; infection screening |
| 11–13⁺⁶ weeks | 1st trimester combined DS screening (nuchal translucency + PAPP-A + free β-hCG) | Down syndrome risk assessment (preferred) |
| 16–19⁺⁶ weeks | 2nd trimester biochemical DS screening (quad screen: AFP, hCG, uE₃, inhibin A) | DS screening if booked late / missed 1st trimester window |
| 18–22⁺⁶ weeks | Morphology (anomaly) scan | Structural anomaly detection |
| 26–30 weeks | 75g OGTT | Gestational diabetes screening |
| 35–37 weeks | GBS (Group B Streptococcus) screening | Intrapartum antibiotic prophylaxis if positive |
Timing Matters
If a woman books late (after 14 weeks), she cannot have 1st trimester combined screening → offer 2nd trimester biochemical screening at 16–19⁺⁶ weeks instead. This was explicitly noted in the lecture: "Or biochemical screening when 16–19 weeks if booked late." [1]
1st trimester combined screening (11–13⁺⁶ weeks):
- Nuchal translucency (NT) on ultrasound: thickened NT ( > 3.5 mm) → increased risk. NT reflects fluid accumulation behind the fetal neck — seen in chromosomal abnormalities, cardiac defects, and other conditions.
- PAPP-A (pregnancy-associated plasma protein A): LOW in Down syndrome
- Free β-hCG: HIGH in Down syndrome
- Combined with maternal age → risk calculation
- Detection rate ~85–90% with 5% false positive rate
2nd trimester biochemical screening (16–19⁺⁶ weeks):
- AFP: LOW in DS (high in NTD)
- hCG: HIGH in DS
- Unconjugated estriol (uE₃): LOW in DS
- Inhibin A: HIGH in DS
- Detection rate ~80% with 5% FPR
Screen positive → offered invasive diagnostic testing (CVS or amniocentesis)
Non-invasive prenatal testing (NIPT / cell-free fetal DNA):
- Analyses cell-free fetal DNA in maternal blood from ~10 weeks
- High sensitivity and specificity for trisomies 21, 18, 13
- It is a screening test, not diagnostic — positive results must be confirmed by invasive testing
- In HK, used as 2nd-tier screening (offered after positive 1st/2nd trimester screening)
Fetal morphology scan at 18–22 weeks [1]
This is a systematic ultrasound survey of fetal anatomy to detect structural anomalies:
- Brain (ventricles, cerebellum, falx)
- Face (lip, palate)
- Spine
- Heart (four-chamber view, outflow tracts)
- Abdominal wall (omphalocele, gastroschisis)
- Kidneys and bladder
- Limbs
- Placenta and amniotic fluid
Prenatal Diagnosis [1]
The objective of diagnosing disorders is to help affected individuals by offering timely treatment, to prevent irreversible damage, or support, if treatment is unavailable. [1]
The lecture provides a detailed flowchart:
Referral → Counselling → Diagnosis (Imaging + Fetal Sampling + Lab Testing) → Results:
- Normal/uncertain result → Delivery → Paediatric assessment → Follow up
- Abnormal result → Counselling → Options: Pregnancy termination / In-utero treatment / Delivery with planned management
- Discrepant result → Confirmation study → Follow up
Invasive tests: Chorionic villus sampling (CVS), Amniocentesis, Cordocentesis. Chromosomal test +/- molecular genetic test as indicated. [1]
| Feature | CVS | Amniocentesis |
|---|---|---|
| Timing | 11–14 weeks | 16–20 weeks |
| Sample | Chorionic villi | Amniocytes from amniotic fluid |
| Lab test | Cytogenetic studies (karyotype/CMA) | Cytogenetic studies (karyotype/CMA) |
| Pain relief | Local analgesia | Not required |
| Miscarriage risk | 0.1–0.2% | 0.1–0.2% |
| Culture failure rate | < 1% | < 1% |
| Turnaround for CMA | 7 working days | 7 working days |
| Maternal risk | Minimal | Minimal |
A normal report does not guarantee that the fetus is free from disorders that are not chromosomal in origin. [1]
Both tests are very accurate. A small proportion of test results may show mosaicism which may require further investigation. [1]
Key Exam Point: Limitations of Invasive Testing
Students often assume a normal karyotype means a normal baby. The lecture explicitly states this is NOT the case. Chromosomal testing does not detect single-gene disorders (unless specifically tested), structural anomalies, or functional problems. Mosaicism can also complicate interpretation — confined placental mosaicism in CVS may not reflect the true fetal karyotype.
Cordocentesis (fetal blood sampling):
- Usually from umbilical vein under USG guidance
- From ~18 weeks onwards
- Used for rapid karyotyping, Hb studies (e.g., α-thal confirmation), fetal infection workup
- Higher miscarriage risk (~1–2%) than CVS/amniocentesis
For α-thalassaemia (both parents carriers of 2 α-gene deletion):
- If < 18 weeks: CVS at 10–12 weeks for DNA study (SEA deletion most common in HK Chinese); or amniocentesis at 18 weeks for DNA study; serial USG at 13, 16, 20, and 30 weeks
- If ≥ 18 weeks: Serial USG to detect hydrops (cardiomegaly, placentomegaly, IUGR, hydropic changes); cordocentesis + Hb study if abnormal USG
For β-thalassaemia (both parents carriers):
- DNA study of parents first to identify mutations
- If mutations identified → CVS (1st trimester) or amniocentesis (2nd trimester) for DNA mutation analysis
- If mutations not identified → prenatal exclusion may not be possible [6]
When a significant risk is identified, couples should be counselled about their reproductive options:
- Natural conception with prenatal diagnosis — accept risk, plan for screening/diagnosis during pregnancy
- Pre-implantation genetic testing (PGT) with IVF — embryos tested before transfer; avoids termination dilemma
- Donor gametes — if one partner has a dominant condition or both are carriers
- Adoption — an option to discuss
- Choosing not to have biological children — valid choice
- Pregnancy continuation with preparation — for conditions compatible with life, plan for neonatal management
- Pregnancy termination — offered when severe anomaly diagnosed; legal framework in HK applies
Counselling Concerns [1]
Counsel = explain, enable others to decide. Advise = explain, recommend a course of action. [1]
This distinction is critical. In genetic/prenatal counselling, the approach should be non-directive — you provide information and support the couple's autonomous decision-making. You do NOT tell them what to do.
Improving the chance of having a healthy child: Prepare before conception; Screen or test after conception; Current tests cannot guarantee a healthy baby for every pregnancy. [1]
Help couples choose the type of screening or diagnostic test that best suits their need. Help couples understand the impact of fetal condition on the family. Help couples choose the course of action for management of fetal abnormality that they will not regret. [1]
Autonomy (informed consent, non-directive counselling, full disclosure, voluntary), Nonmaleficence, Beneficence, Justice (indicated, accessible). [1]
| Principle | Application in Prenatal Counselling |
|---|---|
| Autonomy | Couple makes the final decision; all options presented including continuation of pregnancy; testing is voluntary; informed consent with understanding of risks/benefits/limitations |
| Non-maleficence | Minimise harm — e.g., miscarriage risk of invasive testing; psychological harm of uncertain results |
| Beneficence | Acting in best interest of mother and fetus — early diagnosis allows treatment planning |
| Justice | Fair access to screening regardless of socioeconomic status; publicly funded screening available |
With severe anomaly — may be offered as an option. Refer for second opinion if doctor has conscientious objection to pregnancy termination. [1]
Legal requirements in HK (from CFB OG03): [7]
- Requires opinion of two registered practitioners formed in good faith that:
- (a) Continuance of pregnancy would involve risk to the life/physical or mental health of the pregnant woman greater than if the pregnancy were terminated, OR
- (b) There is substantial risk that the child would suffer from such physical or mental abnormality as to be seriously handicapped
- Must be carried out in a hospital
- After 24 weeks: additional legal requirements; may need court authorization [8]
Integration with Related Topics
| Condition | Current Drug | Pre-Pregnancy Switch | Reason |
|---|---|---|---|
| Epilepsy | Valproate | Lamotrigine or levetiracetam | Valproate most teratogenic AED [5] |
| Hyperthyroidism | Carbimazole/MMZ | PTU (1st trimester) → MMZ (2nd trimester) | MMZ → aplasia cutis, choanal atresia; PTU → hepatotoxicity [2] |
| Hypertension | ACEi/ARB | Labetalol/methyldopa/nifedipine | ACEi → renal dysgenesis, oligohydramnios |
| VTE/Thrombophilia | Warfarin | LMWH | Warfarin crosses placenta; LMWH does not [4] |
| SLE | Mycophenolate | Azathioprine (with specialist input) | Mycophenolate teratogenic |
| Depression | Paroxetine | Sertraline (preferred SSRI in pregnancy) | Paroxetine → cardiac malformations |
The 2023 SAQ tested: "Name one routine antenatal investigation for pregnant woman at 28 weeks and specify what condition to rule out." Answer: 75g OGTT to screen for gestational diabetes mellitus.
- Opt-out screening at booking
- If positive: cART regardless of viral load or CD4 count, started as soon as possible
- Intrapartum: zidovudine + lamivudine + nevirapine at onset of labour
- Neonatal prophylaxis prescribed by paediatrician
- No breastfeeding (in resource-rich settings)
The GP lecture on sexual problems covers counselling during pre-marital checks:
- Results of investigations
- The process of sexual intercourse — private, comfortable environment
- Attitude: respect, tenderness — not being a "spectator"
- Communication and foreplay
- Responsibility to initiate and respond
- Understanding prejudices and unrealistic expectations
- Fatigue as a common barrier
- Hymen — addressing myths and concerns
From the 2022 MCQ: "If the pregnancy is normal, and there are no signs of miscarriage, women can have sexual intercourse during pregnancy." — This is the correct answer. [13]
Likely Exam Questions
-
A 30-year-old woman at pre-marital check has MCV 68 fL, Hb 11 g/dL, HbA₂ 2.5% with occasional HbH bodies. What is the most appropriate advice?
- Answer: Check the MCV of her boyfriend (to assess couple risk for α-thalassaemia). [9]
- Trap: Don't give iron (iron is normal/raised in thalassaemia); folic acid should start before conception, not after confirming pregnancy; IVF is not indicated for thalassaemia carrier alone.
-
Which screening test is performed at 35–37 weeks?
- Answer: GBS screening [1]
-
What is the miscarriage risk of CVS and amniocentesis?
- Answer: 0.1–0.2% for both [1]
-
A couple are both β-thalassaemia carriers. Outline the prenatal diagnostic strategy. (4 marks)
- DNA study of parents to identify mutations → if informative, CVS (11–14 weeks) or amniocentesis (16–20 weeks) for DNA mutation analysis → genetic counselling on options (continuation, termination, adoption) → 1/4 risk of β-thal major per pregnancy
-
List 4 components of pre-pregnancy counselling. (4 marks)
- Medical history review and disease optimization; medication review for teratogenicity; folic acid supplementation; lifestyle modification (stop smoking/alcohol); vaccination review; genetic risk assessment
-
A pregnant woman with epilepsy on valproate. What pre-pregnancy advice? (3 marks)
- Switch to lamotrigine or levetiracetam monotherapy at lowest effective dose; high-dose folic acid 5 mg daily starting 3 months pre-conception; ensure seizure control is stable before conceiving
- With reference to principlism, justify offering prenatal diagnosis and possible termination for severe fetal anomaly. [8]
- Autonomy: informed parents make their own decision; Beneficence: preventing suffering; Non-maleficence: weighing harm of termination vs. harm of severe disability; Justice: equal access to prenatal diagnosis
| Year | Paper | Question | Relevant Topic |
|---|---|---|---|
| 2020 | MCQ | Q6, Q7 | Antenatal investigation matching — MCV, HBsAg, OGTT |
| 2021 | SAQ | Q10 | α-thal carrier parents, selective termination ethics |
| 2022 | MCQ | Q7 | Sexual intercourse during pregnancy |
| 2022 | SAQ | Q10 | Fertility preservation, donor sperm ethics |
| 2023 | MCQ | Q86 | α-thal carrier at pre-marital check — MCV of partner |
| 2023 | SAQ | Q2 | Routine antenatal investigation at 28 weeks (OGTT) |
| 2023 | SAQ | Q5 | HBsAg positive in pregnancy |
| 2024 | MCQ | Q87 | Anti-Ro antibody and congenital heart block |
High Yield Summary
Pre-pregnancy counselling aims to optimize maternal health, identify genetic/medical risks, adjust teratogenic medications, ensure vaccinations, supplement folate, and modify lifestyle BEFORE conception. Risk identification uses detailed history (age, ethnicity, consanguinity, family Hx, medical Hx, meds, obstetric Hx, lifestyle), examination (BP, BMI, heart sounds, cervical screening), and screening tests (CBP with MCV, blood group/Rh, VDRL, HBsAg, rubella Ab, HIV, urine).
Thalassaemia screening is the most tested genetic condition: MCV < 82 → partner testing → Hb electrophoresis. α-thal carrier has normal HbA₂ with HbH bodies; β-thal carrier has raised HbA₂.
Antenatal screening schedule: Booking bloods → 1st trimester DS screening (11–13⁺⁶ wk) → Morphology scan (18–22⁺⁶ wk) → OGTT (26–30 wk) → GBS (35–37 wk).
Invasive testing (CVS 11–14 wk, amniocentesis 16–20 wk): miscarriage risk 0.1–0.2%. A normal result does NOT guarantee a healthy baby.
Counselling is non-directive: explain, enable the couple to decide. Ethical principles: autonomy, non-maleficence, beneficence, justice. Termination for severe anomaly may be offered; refer if conscientious objection.
Active Recall - Lecture Notes
[1] Lecture slides: GC 113. Can we get married Pre-marital, pre-pregnancy and pre-natal counselling.pdf (all pages) [2] Senior notes: Block A - I am losing weight and sweating all the time_ causes of severe, weight loss; thyrotoxicosis; hypothyroidism.pdf (p19) [3] Senior notes: Block A - Many members of the family have anaemia.pdf (p10) [4] Senior notes: Block A - Leg swelling and chest pain_ deep vein thrombosis; pulmonary embolism; Thrombophilia.pdf (p19) [5] Senior notes: Maksim Medicine Notes.pdf (p259) [6] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (p588-589); MBBS Final MB (Medicine) (Felix PY Lai).pdf (p1348-1349) [7] Lecture slides: CFB (OG03) Fertility Regulation.pdf (p6) [8] Past papers: 2021 Fourth Summative SAQ.pdf (Q10, p12) [9] Past papers: 2023 Fourth Summative MCQ.pdf (Q86, p33) [10] Past papers: 2023 Fourth Summative SAQ.pdf (Q2, p3) [11] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (p1070) [12] Lecture slides: MBBS4 t Sexual problems in GP160925.pdf (p24) [13] Past papers: 2022 Fourth Summative MCQ.pdf (Q7, p4)
GC112 Abnormal Vaginal Bleeding Gynaecological Cancer
Abnormal vaginal bleeding in the context of gynaecological cancer refers to irregular, postmenopausal, or otherwise unexplained uterine or vaginal bleeding that may signal an underlying malignancy of the endometrium, cervix, ovary, vagina, or vulva, warranting urgent investigation.
GC114 Climacteric Symptoms Menopause And Related Illness; Amenorrhoea
Climacteric symptoms encompass the vasomotor, psychological, and urogenital manifestations arising from ovarian hormone decline during the menopausal transition, while amenorrhoea refers to the absence of menstruation due to physiological, pathological, or iatrogenic causes.